A research team at the Institut de Neurociències of the Universitat Autònoma de Barcelona (INc-UAB) has developed a new ...

CAR T-cell therapy for cancer leads to similar safety and cancer outcomes in patients with and without preexisting autoimmune ...

A research team at the Institut de Neurociències of the Universitat Autònoma de Barcelona (INc-UAB) has developed a new protein capable of improving ...

Chimeric Therapeutics (ASX:CHM) has announced that the University of Chicago Medicine is now open to enrolling patients in the Phase 1/2 multi-centre ...

Pfizer (PFE) announced that the U.S. FDA has approved the supplemental Biologics License Application for ADCETRIS in combination with lenalidomide ...

Paul Hopper bought 200.00m shares over the last 12 months at an average price of AU$0.008. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on ...

Anti-CD19 chimeric antigen receptor (CD19-CAR)-engineered T cells are approved therapeutics for malignancies. The impact of the hinge domain (HD) and the transmembrane domain (TMD) between the ...

Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case ...

This manuscript describes an important finding of the transcriptional control of a chimeric gene transfer agents (GTA) cluster in Bartonella by a processive anti-termination factor (BrrG). The ...

Interviews revealed what patients and their caregivers focus on and needed support throughout the CAR-T therapy trajectory.